ロード中...
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as sel...
保存先:
| 出版年: | Cell Mol Life Sci |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7904719/ https://ncbi.nlm.nih.gov/pubmed/32851475 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00018-020-03620-w |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|